VERV vs. ATXS, KALV, APLT, YMAB, TVTX, AVTE, ABUS, IGMS, LRMR, and OCS Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Astria Therapeutics (ATXS), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Y-mAbs Therapeutics (YMAB), Travere Therapeutics (TVTX), Aerovate Therapeutics (AVTE), Arbutus Biopharma (ABUS), IGM Biosciences (IGMS), Larimar Therapeutics (LRMR), and Oculis (OCS). These companies are all part of the "pharmaceutical preparations" industry.
Astria Therapeutics (NASDAQ:ATXS ) and Verve Therapeutics (NASDAQ:VERV ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk.
Astria Therapeutics currently has a consensus target price of $22.50, indicating a potential upside of 135.85%. Verve Therapeutics has a consensus target price of $33.00, indicating a potential upside of 451.84%. Given Astria Therapeutics' higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Astria Therapeutics.
99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 2.9% of Astria Therapeutics shares are held by insiders. Comparatively, 21.4% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Astria Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Astria Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
In the previous week, Verve Therapeutics had 14 more articles in the media than Astria Therapeutics. MarketBeat recorded 18 mentions for Verve Therapeutics and 4 mentions for Astria Therapeutics. Verve Therapeutics' average media sentiment score of 0.74 beat Astria Therapeutics' score of 0.60 indicating that Astria Therapeutics is being referred to more favorably in the media.
Astria Therapeutics received 537 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 72.55% of users gave Astria Therapeutics an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
Astria Therapeutics has a net margin of 0.00% compared to Astria Therapeutics' net margin of -1,226.51%. Astria Therapeutics' return on equity of -37.35% beat Verve Therapeutics' return on equity.
Summary Verve Therapeutics beats Astria Therapeutics on 9 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Verve Therapeutics Competitors List
Related Companies and Tools
